The Reduced Intensity Cvd Regimen: A Good Option with Well
Balanced Efficacy/Toxicity Ratio for Elderly Patients with Poor
Status Performance.

a 2008

The Reduced Intensity Cvd Regimen: A Good Option with Well Balanced Efficacy/Toxicity Ratio for Elderly Patients with Poor Status Performance.

HÁJEK, Roman, Lenka ZAHRADOVÁ, Evžen GREGORA, Miroslava SCHÜTZOVÁ, Vladimír KOZA et. al.

Basic information

Original name

The Reduced Intensity Cvd Regimen: A Good Option with Well Balanced Efficacy/Toxicity Ratio for Elderly Patients with Poor Status Performance.

Name in Czech

CVD režim se sníženou intenzitou: dobrá léčebná možnost pro starší pacienty v horším klinickém stavu s vyváženým poměrem účinnoti a toxicity

Authors

Edition

Fiftieth ASH Annual Meeting, 2008

Other information

Type of outcome

Konferenční abstrakt

Confidentiality degree

není předmětem státního či obchodního tajemství

Organization unit

Faculty of Medicine

UT WoS

000262104704317

Keywords in English

multiple myeloma; bortezomib; treatment regimens

Abstract

ORIG CZ

V originále

In this trial, we have evaluated the potential of combinative regimen CVD (Cyclophosphamide, Bortezomib (Velcade), Dexamethasone) reduced intensity (CVD senior; 50% reduction) in elderly pts and/or pts with poor status performance with relapsed MM. The results were compared with CVD junior regimen outcome used at the same time in pts aged < 65 years and good status performance. The reduced CVD senior regimen is tolerated better than CVD junior. Duration of treatment and number of cycles was similar in both regimens. There was no difference in overall response but the higher total dose of bortezomib achieved by pts in each group resulted in a better response in both groups. The reduced intensity CVD regimen seems to be a good option for elderly pts with poor status performance with well balanced efficacy/toxicity ratio.

In Czech

V klinické studii byl hodnocen potenciál léčebného režimu CVD (cyklofosfamid, bortezomib (Velcade), dexametazon) v redukované intenzitě (CVD senior, redukce o 50%) u pacientů s relabovaným mnohočetným myelomem, kteří jsou starší 65 let a/nebo jsou v horším klinickém stavu. Výsledky byly porovnány s výsledky pacientů mladších 65let a v dobrém klinickém stavu, kteří byly léčeni režimem CVD junior (v plných dávkách). Redukovaný režim CDV senior byl tolerován lépe jak CVD junior. Trvání léčby a počet podaných cyklů léčby byl podobný u obou režimů. Nebyl zaznamenán rozdíl v celkové léčebné odpovědi mezi oběma režimy, ale podání vyšší dávky bortezomibu bylo spojeno s lepší léčebnou odpovědí nezávisle na podaném režimu. Režim CVD senior s redukovanou intenzitou se zdá být dobou léčebnou možností pro starší pacienty v horším klinickém stavu s dobrým poměrem účinnost/toxicita.

Citovat

HÁJEK, Roman, Lenka ZAHRADOVÁ, Evžen GREGORA, Miroslava SCHÜTZOVÁ, Vladimír KOZA, Petr PAVLÍČEK, Luděk POUR, Marta KREJČÍ, Viera SANDECKÁ, Andrea KŘIVANOVÁ, Mohamed Abdo Saleh AL-SAHMANI, Dana KRÁLOVÁ and Zdeněk ADAM. The Reduced Intensity Cvd Regimen: A Good Option with Well Balanced Efficacy/Toxicity Ratio for Elderly Patients with Poor Status Performance. In Fiftieth ASH Annual Meeting. 2008.

@proceedings{817050,
   author = {Hájek, Roman and Zahradová, Lenka and Gregora, Evžen and Schützová, Miroslava and Koza, Vladimír and Pavlíček, Petr and Pour, Luděk and Krejčí, Marta and Sandecká, Viera and Křivanová, Andrea and AlandSahmani, Mohamed Abdo Saleh and Králová, Dana and Adam, Zdeněk},
   booktitle = {Fiftieth ASH Annual Meeting},
   keywords = {multiple myeloma; bortezomib; treatment regimens},
   title = {The Reduced Intensity Cvd Regimen: A Good Option with Well Balanced Efficacy/Toxicity Ratio for Elderly Patients with Poor Status Performance.},
   year = {2008}
}

TY  - CONF
ID  - 817050
AU  - Hájek, Roman - Zahradová, Lenka - Gregora, Evžen - Schützová, Miroslava - Koza, Vladimír - Pavlíček, Petr - Pour, Luděk - Krejčí, Marta - Sandecká, Viera - Křivanová, Andrea - Al-Sahmani, Mohamed Abdo Saleh - Králová, Dana - Adam, Zdeněk
PY  - 2008
TI  - The Reduced Intensity Cvd Regimen: A Good Option with Well Balanced Efficacy/Toxicity Ratio for Elderly Patients with Poor Status Performance.
KW  - multiple myeloma
KW  - bortezomib
KW  - treatment regimens
N2  - In this trial, we have evaluated the potential of combinative regimen CVD (Cyclophosphamide, Bortezomib (Velcade), Dexamethasone) reduced intensity (CVD senior; 50% reduction) in elderly pts and/or pts with poor status performance with relapsed MM. The results were compared with CVD junior regimen outcome used at the same time in pts aged < 65 years and good status performance. The reduced CVD senior regimen is tolerated better than CVD junior. Duration of treatment and number of cycles was similar in both regimens. There was no difference in overall response but the higher total dose of bortezomib achieved by pts in each group resulted in a better response in both groups. The reduced intensity CVD regimen seems to be a good option for elderly pts with poor status performance with well balanced efficacy/toxicity ratio.
ER  -

Detailed Information on Publication Record